Last reviewed · How we verify

NCT04142775

Predictors of Intracranial Hemorrhage in ARDS Patients on ECMO

Status unknown Last updated 29 October 2019
What this trial tests

trial testing complication versus no complication in ARDS, Human in 1,000 participants. Status unknown.

Timeline
1 February 2019
Primary endpoint
31 December 2019
31 March 2020

Quick facts

Lead sponsorCharite University, Berlin, Germany
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 February 2019
Primary completion31 December 2019
Estimated completion31 March 2020
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Charite University, Berlin, Germany

Who can join

18 and older, any sex, with ARDS, Human or Extracorporeal Membrane Oxygenation Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intracranial hemorrhage is is a rare, but critical incident in patients with acute lung failure undergoing ECMO therapy. Predictors of intracranial hemorrhage are yet to be defined to identify patients at (high) risk. This retrospective analysis investigates the predictive value and validity of parameters and specific risk factors of critically ill ARDS patients treated with ECMO.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for ARDS, Human

Currently open trials in the same condition.

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04142775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing